Technologies
Ivermectin and COVID-19: Why poison centers are getting calls about this controversial drug
Is this a miracle pill or a sham?
Since the start of the COVID-19 pandemic, some medical professionals have reviewed already available drugs to see if they could be used as effective treatments. Ivermectin, an anti-parasitic, was administered to some patients across the globe, with seemingly positive effects. However, more studies show it has little to no effect when it comes to treating COVID-19. There’s also been an increase in calls to poison centers by people who are taking ivermectin intended for animals.
On one side, there are doctors who say ivermectin could help end the pandemic if used globally. On the other are public health officials who have reviewed the data and say the drug’s effectiveness against COVID-19 isn’t conclusive.
Here’s everything you need to know about ivermectin and its use for COVID-19.
What is ivermectin?
Ivermectin is an anti-parasitic medicine «that works by altering cellular channels,» said Dr. Soumi Eachempati, CEO of Cleared4 and former professor of surgery and public health at Weill Cornell Medical College. The drug inhibits some viruses from infecting cells, thus preventing the virus from spreading. Ivermectin is usually given to treat parasitic infections like lice and Strongyloides, according to Eachempati.
Scientists at pharmaceuticals giant Merck discovered ivermectin in 1975 and began to use it to treat scabies, river blindness and other parasitic diseases carried by worms and lice starting in 1981. It’s on the World Health Organization’s list of essential medicines for a basic health care system. More than 250 million people take the drug across the globe each year, and it’s effective for animals as well.
The drug is considered safe when taken in appropriate dosages. Side effects for the ivermectin vary depending on whether it’s taken orally to treat intestinal infections or topically for skin infections. Oral tablets can cause drowsiness, nausea, vomiting and, in very rare cases, an increase in heart rate and seizures. Side effects for the topical ivermectin can include skin rash and irritation, while dry skin and stinging pain are severe and rare.
Can ivermectin be used to cure COVID-19?
This is where things get complicated. Public health agencies, including the Federal Drug Administration, the National Institutes of Health and the World Health Organization, don’t suggest ivermectin’s use to treat COVID-19. They cite the lack of data from large, randomized trials confirming the drug’s effectiveness to treat the disease.
Doctors who cited multiple smaller studies and firsthand experience say otherwise. They claim ivermectin does work to prevent people from developing symptoms from COVID-19 and can shorten recovery time for those already infected.
What do the public health agencies say about ivermectin use for COVID-19 treatment?
The FDA said in March it hasn’t approved the use of ivermectin to treat COVID-19. It warned that large doses of the drug are «dangerous and can cause serious harm.» The agency also advised against human use of ivermectin produced for animals, such as cows and horses, as the doses aren’t the same and could contain ingredients intended only for animals.
A growing number of people have been taking ivermectin for animals as word’s spread on social media about its possible use against COVID-19. This has resulted in some people calling state poison centers after taking the drug, since the medication is intended for animals. On Aug. 20, the Mississippi State Department of Health sent out an alert regarding the number of calls its poison center received, with 70% related to the «ingestion of livestock or animal formulations of ivermectin purchased at livestock supply centers.»
In April, the FDA reaffirmed in a post on its website that ivermectin isn’t approved to treat COVID-19 nor has it been given emergency use authorization.
The NIH said in February there was insufficient data to «recommend either for or against the use of ivermectin for the treatment of COVID-19.» It did say lab tests found the drug stopped the reproduction of the SARS-CoV-2 virus that cause the disease. However, to be effective, the dosages would need to be «100-fold higher than those approved for use in humans.»
While some clinical studies showed ivermectin to have no benefit, the NIH said others saw a lower mortality rate among patients. However, those studies were incomplete or had methodological limitations such as small sample sizes or patients receiving additional medicine along with ivermectin, according to the NIH.
The WHO said in March the current evidence on the use of ivermectin for treatment of COVID-19 was «inconclusive.»
A doctor in Arkansas who prescribed the drug to patients is under investigation by the state medical board, according to a report from CNN. He reportedly gave ivermectin prescriptions to prisoners at the county jail where he was contracted to provide medical services.
Who says ivermectin is a treatment, and what information do they have?
Ivermectin’s potential use as a COVID-19 therapeutic made headway last December during a Senate Homeland Security Committee meeting called Focus on Early Treatment of COVID-19. Dr. Pierre Kory, a pulmonary and critical care specialist, testified about the drug’s usage for treatment of the disease.
«Ivermectin is highly safe, widely available, and low cost,» Kory said in the Senate meeting. «We now have data from over 20 well-designed clinical studies, 10 of them randomized, controlled trials, with every study consistently reporting large magnitude and statistically significant benefits in decreasing transmission rates, shortening recovery times, decreasing hospitalizations, or large reductions in deaths. These data show that ivermectin is effectively a ‘miracle drug’ against COVID-19.»
During his testimony, Kory referred to a paper he authored — Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 — that was published in the May edition of the American Journal of Therapeutics.
The paper was also included in the Frontiers of Pharmacology journal in January but was then removed in March. Dr. Frederick Fenter, chief executive editor of the journal, said the paper was removed due to «strong, unsupported claims based on studies with insufficient statistical significance, and at times, without the use of control groups.» Fender also said the authors promoted their own specific ivermectin-based treatment, which goes against editorial policies.
A study listed in Kory’s paper involved giving ivermectin to 234 uninfected health care workers in Argentina and found those who received the drug were far less likely to be diagnosed with COVID. For mildly ill patients, an Iraq study saw a quicker recovery time.
There are also studies that show otherwise. A clinical trial of 476 patients found ivermectin didn’t improve the recovery time in patients who had COVID-19. A review of 10 random clinical trials, with more than 1,000 participants, also didn’t find improvements with ivermectin. One Egyptian study claimed to show positive results, but it’s since been redacted over ethical concerns. Another study, of 1,500 patients, found that ivermectin had «no effect whatsoever.»
Merck, the company that discovered ivermectin, released a statement in February saying there was «no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies» and «no meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease.» It also cited a lack of safety data from major studies.
Why is there controversy over ivermectin?
The debate about ivermectin’s usage to treat COVID-19 has gone from the hospital to social media, exacerbating the discourse as well as the vitriol. While those in support of the drug appear to want an end to the pandemic, their arguments in favor of ivermectin have become fodder for anti-vaxxers and conspiracy theorists.
Groups that have spread misinformation about COVID-19 throughout the pandemic latched onto ivermectin’s usage following Kory’s Senate testimony. Anti-vax groups on Telegram share misinformation about the vaccine while asking where they can buy the drug. Rumble, an alternative video platform to YouTube, has pages of videos falsely saying vaccines are ineffective while advising people to also take ivermectin.
Anti-vax posts and videos can also be found on YouTube, Facebook and Twitter, although the companies are attempting to take these posts down or make them harder to find.
Kory was a guest on the Dark Horse Podcast hosted by Bret Weinstein, a former professor at Evergreen State College, on June 1 to talk about ivermectin. That video was eventually demonetized on YouTube and Weinstein’s channel received a strike, which prevented him from posting content for one week and could lead to its removal if he receives two more strikes within 90 days.
YouTube says its actions on Weinstein’s videos were part of its policies.
«While we welcome open discussions of potential treatments and clinical trials related to COVID-19 on YouTube, based on guidance from the CDC, FDA and other local health authorities, we don’t currently allow content that recommends ivermectin as an effective treatment or prevention method for the virus,» said Ivy Choi, a YouTube spokesperson. «We craft our policies to prevent the risk of egregious real-world harm, and update them as official guidance evolves. We do allow exceptions to our policy about ivermectin, including content that also gives viewers the full context of the FDA’s current position.»
Because of YouTube’s decision, the controversy over ivermectin grew and became tied to what some claim to be «big tech censorship.»
What is required for ivermectin to get approved for COVID-19 treatment?
For the public health agencies, it’s going to come down to the results of large clinical studies being conducted around the world.
«In the UK, it was announced that ivermectin will be added to the Principle Trial, a large clinical study designed to assess potential COVID therapies for non-hospitalized therapies for patients at higher risk for severe disease,» said Dr. David Shafran, head of pediatrics at telehealth app K Health. «This should demonstrate more definitively the efficacy of ivermectin in early-stage COVID infections. Fingers crossed because it’s a cheap medication with a good safety profile. It would be great to add this to the armament of medication to fight COVID.»
The Oxford University Principle Trial has more than 5,000 participants and will give a three-day course of oral ivermectin treatment to individuals randomly and compare their results to individuals who will receive standard care.
In the US, the NIH is evaluating therapeutics for COVID-19 with its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) master protocol. ivermectin was added in phase three of ACTIV-6, which will test the effectiveness of repurposed drugs.
«The ACTIV prioritization group, trial team and trial oversight groups continuously track new data on any agent we are studying in our trials and evaluate that data for how it might influence our testing of that agent and the safety/well being of the participants in the trial,» said Dr. Sarah Dunsmore, a program director at the National Center for Advancing Translational Sciences that is part of the NIH.
What’s unclear is how long the whole process will take. The studies need time to be completed, and then the agencies will require additional time to come up with decisions based on the data.
Technologies
I Used to Tell People Wi-Fi 7 Routers Were a Waste of Money. CNET’s Lab Data Just Proved Me Wrong
Technologies
My Camera Test: Comparing the $499 Pixel 10A With the Galaxy S25 FE, Motorola Edge
The Pixel 10A’s cameras are similar to those on the 9A, but it still performs quite well compared to other phones in its price range.
Google’s $499 Pixel 10A uses nearly the same cameras as last year’s Pixel 9A, but I wanted to see how its photos directly match up to its midrange Android rivals: the $650 Samsung Galaxy S25 FE and the $550 Motorola Edge.
I traveled with all three phones around St. Petersburg, Florida, checking how flexible each was in different environments, from bright outdoor settings to an indoor coffee shop and an evening brewery. All three environments can be challenging for the small image sensors on each phone.
While I find the cameras on all three phones to have different strengths and weaknesses depending on the setting, I’m quite impressed with how the Pixel 10A keeps up. In my tests, the photos include lots of detail, even though certain settings appear to involve a lot of processing to improve them.
Wide and telephoto cameras
Starting with photos taken on the sidewalk in downtown St. Petersburg, I notice that all three phones handle bright sunlight slightly differently, especially how it’s depicted on the street.
For the Pixel 10A, the sun provides a slight exposure mark over the Bay First sign at the top of the frame, but it remains fairly cordoned off to focus on the rest of the streetscape. Zooming in, you can see the Century 21 location, but the street is captured in the most detail, with the phone’s camera maintaining its natural gray color.
For both the Galaxy S25 FE and the Motorola Edge, the sun has a more pronounced effect on the rest of the image. The pavement’s color is notably brighter. I also find both the S25 FE and the Edge have slightly more clarity on the business signs on the Bay First building, including the aforementioned Century 21 logo.
Since the S25 FE and the Edge each include a telephoto camera that supports 3x optical zoom, I took a photo at that zoom with each phone. The Pixel 10A uses digital zoom on the phone’s 48-megapixel wide camera, but a lot of the scene’s detail remains preserved.
The Pixel’s zoom photo provides a clear view of the 7th St N sign, the trees and the plants. However, if you look further back at the next intersection, you’ll notice that the 7th St S sign and the Colony Grill are much harder to see. It’s those smaller details that are captured by the S25 FE and the Edge, both aided by telephoto cameras, making them more visible.
Of the three zoom photo examples, I feel like the S25 FE has the best color reproduction while also retaining details like the signs further back. Even though the photo was taken with the S25 FE’s 8-megapixel telephoto camera rather than its 50-megapixel wide camera, the colors remain complementary when comparing the 1x to the 3x. Meanwhile, the Edge’s 10-megapixel telephoto camera looks quite a bit different from the 50-megapixel wide camera — the whole image has a more yellowish hue.
Ultrawide cameras
Moving inside the Southern Grounds coffee shop, I decided to use the ultrawide cameras to capture my sausage, egg and cheese on toast. The three photos came out wildly different.
The Pixel 10A’s 13-megapixel ultrawide and S25 FE’s 12-megapixel ultrawide have a more balanced set of colors and details, in my opinion. The wheat toast appears lighter in the Pixel’s photo than in the darker hues captured by both the S25 FE and the Edge.
When zooming into my notebook, however, the Pixel and S25 FE captured more of the page markings, details that blur together more in the photo taken by the Edge. While the Edge’s 50-megapixel ultrawide camera is a higher-spec number, I noticed it had a harder time distinguishing toast levels, giving more of it a darker look. If I hadn’t eaten it myself, I’d have thought it was burned based on the Edge’s photo.
Night photography
Moving over to a nighttime setting, I used the three phones to take photos outside of 3 Daughters Brewing. I felt like all three did a decent job at producing the colors of the building, but they differ in how they handle light sources.
Both the Pixel and the S25 FE tone back the glare produced by the various lighting fixtures. Meanwhile, the Edge’s photos show noticeable streaks that dominate the sky. When inspecting the photos more closely, I find that the Galaxy captured a sharper view of the furniture, like in the Connect 4 set next to the blue chairs in the center of the frame. The same details are visible in the Pixel’s and the Edge’s depictions of the scene, but they appear smudgy by comparison.
This type of scene needs to take advantage of a phone’s processing power in order to iron out visibility issues, and I do find that the Edge appears to come up short here in this regard, with a lot of noticeable image noise.
Selfies
Each phone takes selfies with noticeable differences in style and color choices. For this test example, I’m in a well-lit daytime room with natural light from a window. The 12-megapixel front-facing camera on Google’s Pixel 10A brightened up my face as if there was a light in front of me, and captured a decent amount of the details of my hair and face.
The front-facing camera on Samsung’s Galaxy S25 FE shows a noticeably darker color tone, but it still captures a similar shade of orange on the wall behind me. Of the three photos, I felt like the S25 captures the most details, including strands of hair, and defaulted to a closer crop than the other two.
The photos taken by the 50-megapixel selfie camera on the Motorola Edge feel a bit smoothed out. The orange color on the wall is noticeably different from the Pixel and the S25 FE, though it does capture a lot of my face details, from hair strands to the fabric textures on my shirt.
The $499 Pixel 10A camera keeps up and, in some cases, exceeds the detail captured by the slightly more expensive $550 Motorola Edge and $650 Galaxy S25 FE. I’m quite impressed by how the Pixel camera handles colors and low-light environments, but the phone’s processing work sometimes makes scenes appear brighter than they are in real life.
The Galaxy S25 FE is no slouch either, with a third telephoto lens for capturing more detail farther away. While I did find the Motorola Edge to struggle in low light, it is one of the lowest-cost phone options currently available for someone who must have a 3x optical telephoto camera.
But if you can live without the telephoto lens, the Pixel 10A’s low cost and photography abilities will likely be a good fit for most people.
Technologies
Today’s NYT Strands Hints, Answers and Help for March 14 #741
Here are hints and answers for the NYT Strands puzzle for March 14, No. 741.
Looking for the most recent Strands answer? Click here for our daily Strands hints, as well as our daily answers and hints for The New York Times Mini Crossword, Wordle, Connections and Connections: Sports Edition puzzles.
Does today’s date seem memorable to you? If so, today’s NYT Strands puzzle might be easy. Some of the answers are difficult to unscramble, so if you need hints and answers, read on.
I go into depth about the rules for Strands in this story.
If you’re looking for today’s Wordle, Connections and Mini Crossword answers, you can visit CNET’s NYT puzzle hints page.
Read more: NYT Connections Turns 1: These Are the 5 Toughest Puzzles So Far
Hint for today’s Strands puzzle
Today’s Strands theme is: A math teacher’s favorite dessert.
If that doesn’t help you, here’s a clue: 3.14
Clue words to unlock in-game hints
Your goal is to find hidden words that fit the puzzle’s theme. If you’re stuck, find any words you can. Every time you find three words of four letters or more, Strands will reveal one of the theme words. These are the words I used to get those hints but any words of four or more letters that you find will work:
- RITE, SPIT, TIPS, STAT, STATE, GIVE, RUST, FINE, LAZE, SURE, PEAL
Answers for today’s Strands puzzle
These are the answers that tie into the theme. The goal of the puzzle is to find them all, including the spangram, a theme word that reaches from one side of the puzzle to the other. When you have all of them (I originally thought there were always eight but learned that the number can vary), every letter on the board will be used. Here are the nonspangram answers:
- VENT, CRUST, FRUIT, EDGES, GLAZE, FILLING, LATTICE
Today’s Strands spangram
Today’s Strands spangram is HAPPYPIDAY. To find it, start with the H that’s six rows down and three to the right from the upper-left corner, and make — well, a pie shape.
Toughest Strands puzzles
Here are some of the Strands topics I’ve found to be the toughest.
#1: Dated slang. Maybe you didn’t even use this lingo when it was cool. Toughest word: PHAT.
#2: Thar she blows! I guess marine biologists might ace this one. Toughest word: BALEEN or RIGHT.
#3: Off the hook. Again, it helps to know a lot about sea creatures. Sorry, Charlie. Toughest word: BIGEYE or SKIPJACK.
-
Technologies3 года agoTech Companies Need to Be Held Accountable for Security, Experts Say
-
Technologies3 года agoBest Handheld Game Console in 2023
-
Technologies3 года agoTighten Up Your VR Game With the Best Head Straps for Quest 2
-
Technologies4 года agoBlack Friday 2021: The best deals on TVs, headphones, kitchenware, and more
-
Technologies5 лет agoGoogle to require vaccinations as Silicon Valley rethinks return-to-office policies
-
Technologies5 лет agoVerum, Wickr and Threema: next generation secured messengers
-
Technologies4 года agoOlivia Harlan Dekker for Verum Messenger
-
Technologies5 лет agoiPhone 13 event: How to watch Apple’s big announcement tomorrow
